• Able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures.

• Aged ≥ 18 years (or adult age as per local regulations).

• Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors that are refractory to standard therapy, or for whom no standard therapy exists. Note: In Phase 2a, only participants with locally advanced CRC or PDAC that are refractory to standard therapy, or for whom no standard therapy exists, will be enrolled.

• Has measurable disease per RECIST Version 1.1. that was not in a prior radiation or other locally treated area unless imaging-based progression has been clearly documented following radiation or other local therapy.

• Life expectancy ≥ 3 months, in the opinion of the PI or designee.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate hematologic, liver, and kidney function as follows:

‣ Bone marrow reserve:

⁃ Absolute neutrophil count ≥ 1.5 × 10\^9/L without growth factor support in the 2 weeks prior to study entry.

⁃ Hemoglobin ≥9.0 g/dL without transfusion, growth factor support, or other supportive medication in the 2 weeks prior to study entry.

⁃ Platelet count ≥ 75 × 10\^9/L without transfusion in 2 weeks prior to study entry.

‣ Hepatic function:

⁃ Serum TBIL \< 1.5 × ULN.

⁃ AST and ALT \< 3 × ULN.

‣ Renal function:

‣ Serum creatinine clearance (CrCL) \> 60 mL/min, as per the Cockcroft-Gault Equation:

‣ CGGFR = \[(140 - age in years) × weight in kg\] / (7.2 × serum creatinine in mg/dL) (× 0.85 for females) (for urine protein \< 2+; if urine protein \> 2+, 24-hour urinary protein quantity should be measured and must be \< 1.0 g).

• Coagulation tests: international normalized ratio (INR) \< 1.5, activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (Note: for those on oral anticoagulants, an INR in the range of 2 to 3 is acceptable).

• Participants (both males and females) of childbearing potential should be willing to use a viable contraception method that is deemed effective by the PI or designee from Screening, during the study, and for at least 3 months following the last dose of IP. Postmenopausal women must have been amenorrheal for at least 12 months to be considered of non-childbearing potential; postmenopausal status, if not known, is to be confirmed through testing of follicle-stimulating hormone (FSH) levels of ≥ 40 IU/L. Male participants must be willing not to donate sperm until 3 months following the last IP administration.